Hepatitis C viral IRES inhibition by phenazine and phenazine-like molecules

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 11, 2000, Pages 1151-1154

  Wang, Wuyi ^a   Préville, Patrice ^a   Morin, Nicolas ^a   Mounir, Samir ^a   Cai, Weizhong ^b   Siddiqui, M Arshad ^a  

^a Shire Canada   (Canada)

^b OSI PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENAZINE; PHENAZINE DERIVATIVE;

ARTICLE; CELL LINE; CHEMICAL MODIFICATION; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; GENE EXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; RIBOSOME; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTIVIRAL AGENTS; HEPACIVIRUS; PHENAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0342699722     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00217-1     Document Type: Article

References (22)

1. (a) World Health Organization. Hepatitis C: global prevalence. Weekly Epidemiological Record 1997, 10, 65.
2. (b) Alter, M. J.; Margolis, H. S.; Krawczynsk, K.; Judson, F. N.; Mares, A.; Alexander, W. J.; Hu, P. Y.; Gerber, M. A.; Sampliner, R. E.; Meeks, E. L.; Beach, M. J. N. Engl. Med. 1992, 327, 1899.
3. (a) Bartenschlager, R. Intervirology 1997, 40, 378.
4. (b) Okamoto, H.; Miyakawa, Y.; Mayumi, M. Viral Hepatitis 1997, 3, 51.
5. (a) Gallinari, P.; Brennan, D.; Nardi, C.; Brunetti, M.; Tomei, L.; Steinkuler, C.; Francesco, R.-D. J. Virol. 1998, 72, 6758.
6. (b) Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H. J. Virol., 1993, 67, 3835.
7. (c) Lin, C.; Thomson, J. A.; Rice, C. M. J. Virol. 1995, 69, 14373.
8. (d) Kim, J. L.; Morgenstern, K. A.; Lin, C.; Fox, T.; Dwyer, M. D.; Landro, J. A.; Chambers, S. P.; Markland, W.; Lepre, C.; O'Malley, E. T.; Harbeson, S. L.; Rice, C. M.; Murcko, M. A.; Caron, P. R.; Thomson, J. A. Cell 1996, 87, 343.
9. For NS3 helicase functions: (a) Kim, J. L.; Morgenstern, K. A.; Griffith, J. P.; Dwyer, M. D.; Thomson, J. A.; Murcko, M. A.; Lin, C.; Caron P.; Structure 1998, 6, 89.
10. (b) Cho, H.-S.; Ha, N.-C.; Kan, L.-W.; Chung, K. M.; Back, S. H.; Jang, S. K.; Oh, B.-H. J. Biol. Chem. 1998, 273, 15045.
11. Behrens S.-E., Tomei L., De Francesco R. EMBO. 15:1996;12-22.
12. (a) Fukushi, S.; Kurihara, C.; Ishiyama, N.; Hoshino, F. B.; Oya, A.; Katayama, K. J. Virol. 1997, 71, 1662.
13. (b) Lu, H.-H.; Wimmer, E. Proc. Natl. Acad. Sci. USA 1996, 93, 1412.
14. (a) Ikeda, M.; Sakai, S.; Tsuai, I.; Zuao, I.; Ryan, H.; Iyan, S.; Kai, Y.; Kako, Y.; Tsukada, I.; Yanagisawa, M. JP8268890, 1996.
15. (b) Kai, Y.; Sasho, M.; Kaku, Y.; Tsukada, I.; Yanagisawa, M. JP7069899, 1996.
16. (a) Wang, C.; Sarnow, P.; Siddiqui, A. J. Virol. 1994, 68, 7301.
17. 4 cells/well in a 96-well plate. The compounds were then added at various concentrations in a final DMSO concentration of 0.2% and incubate 24 h at 37 °C. Following the incubation the cells were washed twice in PBS. 50 μL of Luciferin lysis buffer is added and kept for 10 min in the dark. Cells were then re-suspended and 80 μL was taken on a white 96-well plate for Luciferase activity.
18. Plumb A.J., Milroy R., Kaye S.B. Cancer Res. 49:1989;4435.
19. A molecular mechanics calculation using HyperChem program suggests, in addition to the widened angle, a slight pyramidal configuration for the central nitrogen atom in structures 2 and 3.
20. +: 227. All commercial compounds showed purity 〉90% by HPLC analysis.
21. Klunder J.M., Hargrave K.D., West M., Cullen C., Pal K., Behnke M.L., Kapadia R.S., McNeil D.J., Wu J.C., Chow G.C., Adams J. J. Med. Chem. 35:1992;1887.
22. Zauberman, A.; Nussbaum, O.; Ilan, E.; Eren, R.; Ben-Mosh, O.; Arazi, Y.; Berre, S.; Lubin, I.; Shouval, D.; Galun, E.; Reiser, Y.; Dagan, S. 6th International Symposium on Hepatitis C and Related Virus. Molecular Virology and Pathagenesis, Bethesda, MD, USA, 6-9 June, 1999, Abstract # 4.3.